- Home
- MLYS vs MPB Comparison
MLYS vs MPB Comparison
Compare MLYS & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- MPB
- Stock Information
- Founded
- MLYS 2019
- MPB 1868
- Country
- MLYS United States
- MPB United States
- Employees
- MLYS N/A
- MPB N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- MPB Major Banks
- Sector
- MLYS Health Care
- MPB Finance
- Exchange
- MLYS Nasdaq
- MPB Nasdaq
- Market Cap
- MLYS 634.6M
- MPB 525.0M
- IPO Year
- MLYS 2023
- MPB N/A
- Fundamental
- Price
- MLYS $9.77
- MPB $29.78
- Analyst Decision
- MLYS Strong Buy
- MPB Buy
- Analyst Count
- MLYS 2
- MPB 2
- Target Price
- MLYS $30.00
- MPB $36.00
- AVG Volume (30 Days)
- MLYS 266.6K
- MPB 67.9K
- Earning Date
- MLYS 11-11-2024
- MPB 01-28-2025
- Dividend Yield
- MLYS N/A
- MPB 2.68%
- EPS Growth
- MLYS N/A
- MPB 14.41
- EPS
- MLYS N/A
- MPB 2.91
- Revenue
- MLYS N/A
- MPB $173,416,000.00
- Revenue This Year
- MLYS N/A
- MPB N/A
- Revenue Next Year
- MLYS N/A
- MPB $19.26
- P/E Ratio
- MLYS N/A
- MPB $10.26
- Revenue Growth
- MLYS N/A
- MPB 4.93
- 52 Week Low
- MLYS $8.58
- MPB $19.20
- 52 Week High
- MLYS $16.91
- MPB $33.87
- Technical
- Relative Strength Index (RSI)
- MLYS 37.52
- MPB 55.01
- Support Level
- MLYS $9.18
- MPB $28.48
- Resistance Level
- MLYS $9.97
- MPB $29.25
- Average True Range (ATR)
- MLYS 0.85
- MPB 0.70
- MACD
- MLYS -0.25
- MPB 0.23
- Stochastic Oscillator
- MLYS 24.53
- MPB 93.36
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.